These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 39407338

  • 21. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [Abstract] [Full Text] [Related]

  • 22. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.
    Clin Infect Dis; 2015 Jan 15; 60(2):188-94. PubMed ID: 25320286
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, Li YP, Zhang ZM, Fan L.
    BMC Infect Dis; 2022 Aug 29; 22(1):715. PubMed ID: 36038829
    [Abstract] [Full Text] [Related]

  • 24. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H, van den Hof S, Cobelens F, Zhou Y, Zhao B, Wang S, Zhao Y.
    BMC Infect Dis; 2020 Jan 07; 20(1):19. PubMed ID: 31910878
    [Abstract] [Full Text] [Related]

  • 25. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, Isbaniah F, Dowdy DW.
    Int J Tuberc Lung Dis; 2014 May 07; 18(5):564-70. PubMed ID: 24903794
    [Abstract] [Full Text] [Related]

  • 26. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
    Alene KA, Viney K, McBryde ES, Gray DJ, Melku M, Clements ACA.
    Transbound Emerg Dis; 2019 Jul 07; 66(4):1611-1618. PubMed ID: 30924283
    [Abstract] [Full Text] [Related]

  • 27. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.
    Int J Tuberc Lung Dis; 2012 Oct 07; 16(10):1335-43. PubMed ID: 23107633
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A, Khan AH, Ahmad N, Ghafoor A.
    J Infect Public Health; 2024 Sep 07; 17(9):102522. PubMed ID: 39173557
    [Abstract] [Full Text] [Related]

  • 29. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
    Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Subay S, Adiono SH.
    Int J Mycobacteriol; 2024 Apr 01; 13(2):140-146. PubMed ID: 38916383
    [Abstract] [Full Text] [Related]

  • 30. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China.
    Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, Zhu L.
    BMC Infect Dis; 2018 Mar 06; 18(1):114. PubMed ID: 29510666
    [Abstract] [Full Text] [Related]

  • 31. Culture conversion and six months interim outcomes in retreatment cases of pulmonary MDRTB - a six month interim analysis.
    Batool R, Khan SW, Imran M, Barry Z, Ali SZ.
    J Pak Med Assoc; 2021 Dec 06; 71(12):2710-2716. PubMed ID: 35150525
    [Abstract] [Full Text] [Related]

  • 32. Determinants of sputum culture conversion time in multidrug-resistant tuberculosis patients in ALERT comprehensive specialized hospital, Addis Ababa, Ethiopia: A retrospective cohort study.
    Abebe M, Atnafu A, Tilahun M, Sero N, Neway S, Alemu M, Tesfaye G, Mihret A, Bobosha K, Wan C.
    PLoS One; 2024 Dec 06; 19(5):e0304507. PubMed ID: 38820260
    [Abstract] [Full Text] [Related]

  • 33. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, Padanilam X, Reuter A, Romero R, Ismail F, Enwerem M, Ferreira H, Conradie F, Naidoo K, Menzies D.
    Lancet Infect Dis; 2022 Jul 06; 22(7):1042-1051. PubMed ID: 35512718
    [Abstract] [Full Text] [Related]

  • 34. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D, Ameya G, Haile K, Abreha G, Worku Y, Debela T.
    Ann Clin Microbiol Antimicrob; 2018 Jul 03; 17(1):30. PubMed ID: 29970076
    [Abstract] [Full Text] [Related]

  • 35. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 03; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 36. Influence of previous tuberculosis treatment history on acid-fast bacilli smear and culture conversion.
    Lee J, Lee BJ, Yoon HI, Lee CT, Lee JH.
    Int J Tuberc Lung Dis; 2012 Oct 03; 16(10):1344-8. PubMed ID: 23107634
    [Abstract] [Full Text] [Related]

  • 37. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
    Mbelele PM, Mpolya EA, Sauli E, Mtafya B, Ntinginya NE, Addo KK, Kreppel K, Mfinanga S, Phillips PPJ, Gillespie SH, Heysell SK, Sabiiti W, Mpagama SG.
    J Clin Microbiol; 2021 Mar 19; 59(4):. PubMed ID: 33536294
    [Abstract] [Full Text] [Related]

  • 38. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.
    Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O, Agdestein A, Tessema GT, Tønjum T, Yimer SA.
    PLoS One; 2020 Mar 19; 15(8):e0236362. PubMed ID: 32797053
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.
    Abraham Y, Assefa DG, Hailemariam T, Gebrie D, Debela DT, Geleta ST, Tesfaye D, Joseph M, Manyazewal T.
    BMC Infect Dis; 2024 Oct 01; 24(1):1087. PubMed ID: 39354416
    [Abstract] [Full Text] [Related]

  • 40. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, Xue Z, Li L, Xu S, Pang Y.
    Int J Infect Dis; 2021 Jan 01; 102():392-396. PubMed ID: 33130209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.